Takhzyro denied for failing step therapy by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for takhzyro are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Requires Step Therapy for Takhzyro — and How to Appeal

Step-therapy denials for Takhzyro (lanadelumab) occur when UHC's coverage policy requires documented trial of one or more other HAE prophylactic agents before approving Takhzyro. UHC may require a trial of a plasma-derived C1-esterase inhibitor concentrate or another available prophylactic before authorizing a subcutaneous monoclonal antibody. This policy exists because older prophylactic agents have lower per-unit costs, even if their dosing burden and attack-prevention profile differ.

This is a common and frequently overturned denial when your prescriber documents either (a) that you have already tried the required prior-step agents and they were inadequate, or (b) that a clinical exception applies — such as a contraindication, intolerance, access barrier, or specific clinical characteristic that makes the step-therapy requirement inapplicable to your case.

## Federal Appeal Rights

• ACA §2719 / ERISA §503 protect your right to internal appeal and independent external review.
• Internal appeal deadline: 180 days from the denial notice.
• External review window: approximately 4 months after final internal denial.
• Expedited review (72-hour decision) is appropriate given HAE's potential to cause life-threatening laryngeal attacks — document the urgency explicitly.

## Appeal Timeline

1. Request the full denial letter and the operative step-therapy policy with the specific agents and criteria required. 2. Review your chart to identify whether you have already tried any required step agents. 3. File a written internal appeal with complete documentation. 4. UHC must respond within 30 days (standard) or 72 hours (expedited). 5. If denied, escalate immediately to external IRO.

## Documentation to Gather

• Diagnosis confirmation: Genetic or laboratory confirmation of HAE type.
• Prior step-agent trial history: For each agent named in UHC's step-therapy requirement, provide chart documentation with start date, end date, doses used, and documented outcome (inadequate response, adverse event, intolerance, or contraindication).
• Attack history during prior therapy: If you experienced breakthrough attacks on a required step agent, document frequency and severity.
• Clinical exception basis: If you have not tried a required step agent, your prescriber must document the clinical reason — intolerance risk, contraindication per the label, or a clinical characteristic that makes the step agent inappropriate.
• Step-therapy exception statute (if applicable): Many states have enacted step-therapy exception laws requiring plans to grant exceptions in defined circumstances — your prescriber or a patient advocate can identify whether your state's law applies.
• Prescriber specialist letter: Detailed letter from your allergist, immunologist, or HAE specialist explaining why Takhzyro is the appropriate therapy at this time, referencing applicable professional guideline organizations.

## Criteria-Mapping Structure

Obtain UHC's current step-therapy policy for Takhzyro and complete a one-to-one mapping:

| Step Requirement | Documentation Response | |---|---| | Trial of [Step 1 agent] with inadequate response | [Chart note: dates, outcome] | | Trial of [Step 2 agent] if required | [Chart note: dates, outcome, or exception rationale] | | Clinical exception criteria (if applicable) | [Prescriber attestation + state law citation if applicable] |

Cross-reference UHC's required step agents against the FDA-approved prescribing information for each at DailyMed, and confirm your prescriber's letter addresses the specific agents named in UHC's policy by name.